Zhao Yalei, Zhang Lingjian, Ouyang Xiaoxi, Jiang Zhengyi, Xie Zhongyang, Fan Linxiao, Zhu Danhua, Li Lanjuan
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China.
Eur J Clin Invest. 2019 Jun;49(6):e13098. doi: 10.1111/eci.13098. Epub 2019 Mar 20.
There is a complex oxidant and antioxidant system that maintains the redox homoeostasis in the liver. While suffering from exogenous or endogenous risk factors, the balance between oxidants and antioxidants is disturbed and excessive reactive oxygen species are generated, resulting in oxidative stress. Oxidative stress is prevalent in various liver diseases and is thought to be involved in their pathophysiology. Advanced oxidation protein products are generated under conditions of oxidative damage and are newly described protein markers of oxidative stress. Previous studies have underscored the universal pathogenic roles of oxidation protein products in various diseases. However, investigations into how these products participate in the development of liver diseases have been superficial and insufficient. In this review, we highlight the current understanding of the roles of advanced oxidation protein products in liver disease pathogenesis and the underlying mechanisms. Moreover, we summarize the current studies on advanced oxidation protein products in infectious and noninfectious, acute and chronic liver diseases. Different strategies for targeting these advanced oxidation protein products and future perspectives, which may pave the way for developing new therapeutic strategies, will also be discussed here.
存在一个复杂的氧化剂和抗氧化剂系统，可维持肝脏中的氧化还原稳态。当遭受外源性或内源性风险因素时，氧化剂和抗氧化剂之间的平衡被打破，会产生过量的活性氧，从而导致氧化应激。氧化应激在各种肝脏疾病中普遍存在，并被认为参与了其病理生理过程。晚期氧化蛋白产物在氧化损伤条件下产生，是新描述的氧化应激蛋白标志物。先前的研究强调了氧化蛋白产物在各种疾病中的普遍致病作用。然而，关于这些产物如何参与肝脏疾病发展的研究一直很肤浅且不充分。在这篇综述中，我们重点介绍了目前对晚期氧化蛋白产物在肝脏疾病发病机制中的作用及其潜在机制的理解。此外，我们总结了目前关于晚期氧化蛋白产物在感染性和非感染性、急性和慢性肝脏疾病中的研究。这里还将讨论针对这些晚期氧化蛋白产物的不同策略以及未来展望，这可能为开发新的治疗策略铺平道路。
